Regulation of CCL18 by Corticosteroids in Severe Asthma
NCT ID: NCT03779152
Last Updated: 2018-12-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
48 participants
OBSERVATIONAL
2009-02-28
2017-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
non asthmatic subjects
No interventions assigned to this group
intermittent asthmatics
No interventions assigned to this group
severe asthmatics sensitive to corticosteroids
No interventions assigned to this group
severe asthmatics resistant to corticosteroids
No interventions assigned to this group
moderate asthmatics
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* non-atopic and non-smoking
* cutting to negative pneumoallergens,
* Total IgE levels less than 100 ku / L
* no clinical history of asthma
* without background treatment
2. patients with intermittent asthma =
* being asymptomatic between asthma attacks,
* with symptoms less than once a week
* having a forced expiratory volume per second (FEV1) of at least 80% of the theoretical.
* treated by ß2 mimetics on demand and will not have inhaled corticosteroids.
3. severe asthma insensitive to corticosteroid therapy =
* continuous or nearly continuous treatment with oral corticosteroids (≥ 50% of the year) / or treatment with IC ≥ 1500 microg beclomethasone dipropionate equivalent (BDP)\] airway obstruction fixed with FEV1 ranging from less than 15% after 7 days of oral corticosteroid therapy to 40 mg / day of prednisolone;
* Followed at the immunoallergology pneumology consultation for at least 1 year will be recruited.
4. Severe corticosensitive asthma = continuous or near continuous treatment with oral corticosteroids (≥ 50% of the year) / or treatment with IC ≥ 1500 microg beclomethasone dipropionate equivalent (BDP)\]
* reversibility of FEV1 after treatment with oral corticosteroids.
* Followed at the immunoallergology pneumology consultation for at least 1 year will be recruited.
5. controlled moderate asthma treated with inhaled corticosteroids \<1500μg equivalent of beclomethasone dipropionate and with: ß2 long-acting mimetics (or anti-leukotriene, or theophylline) for at least 6 months.
Exclusion Criteria
* active smoking
* pregnant or lactating women
* have received oral corticosteroid treatment in the previous 3 weeks,
* have received non-steroidal anti-inflammatory drugs (NSAIDs) in the previous 2 weeks.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Lille
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Benoit Wallaert, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Lille
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Calmette, CHRU
Lille, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-A00370-55
Identifier Type: OTHER
Identifier Source: secondary_id
2008/0813
Identifier Type: -
Identifier Source: org_study_id